Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07505771 · ClinicalTrials.gov registry record · Early Phase 1
A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer
A Early Phase 1 study, sponsored by Immunome.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 105
- Enrollment target
NCT07505771 is a Early Phase 1 study that is actively recruiting participants, run by Immunome. The registered enrollment target is 105 participants.
The verdict
NCT07505771, a Early Phase 1 study, is actively recruiting participants, sponsored by Immunome.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.
Interventions
- DRUG 177Lu-IM-3050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2026-06 |
| Est. Completion | 2034-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07505771
The ClinicalTrials.gov registry entry for NCT07505771 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunome, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 177Lu-IM-3050 is the first listed.
NCT07505771 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07505771 about?
NCT07505771 is a clinical study titled "A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer". IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.
What is the current status of trial NCT07505771?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 105 participants. The study started on 2026-06. Estimated completion is 2034-12.
What interventions are being tested in trial NCT07505771?
The interventions under investigation include: 177Lu-IM-3050 (DRUG).
Who is sponsoring clinical trial NCT07505771?
This trial is sponsored by Immunome, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.